Project Grant R16AI182345
- This Project Grant award of $233,250.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to determine the role of the Brucella TIR-NAD hydrolase activity in immunosuppression and pathogenesis. The research will focus on the Brucella species, which are highly pathogenic for humans, to test the hypothesis that TIR-mediated NAD+ hydrolysis directly contributes to bacterial...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $105,076 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Dartmouth College to study the dual function of the T6SS immunity protein TSIT in regulating Pseudomonas aeruginosa biofilm growth. The research aims to test the hypothesis that TSIT acts as a transcription factor, in addition to its role as a T6SS immunity protein, to regulate biofilm formation - a key...
- This Project Grant award of $104,262, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore the relationship between genetic variants, transcriptional responses, and tuberculosis (TB) infection outcomes in macrophages derived from genetically diverse mice. The project aims to understand the basis for variability in TB infection outcomes, which may help identify ways to...
- This $453,750 Project Grant was awarded on August 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to study how certain bacteriophages (phages) can evade the antiviral defense mechanisms of bacteria, including deadly pathogens like Vibrio cholerae. The research aims to determine the counter-defense mechanisms used by a specific phage protein to antagonize the...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research grant program (CFDA 93.855), provides $463,676 to the University of Maryland, Baltimore for research to enhance the understanding of Fc-mediated effector functions in the context of infectious diseases. The project aims to dissect the mechanisms underpinning Fc-mediated effector functions, with a focus on antibody interactions with a...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $430,285 Project Grant to Towson University to investigate RTA-induced ubiquitination in Kaposi's Sarcoma Herpesvirus (KSHV) for the period of February 1, 2025 to January 31, 2028. The project aims to identify cellular targets for intervention by studying novel virus-host interactions involving the cellular ubiquitin-proteasome...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $490,093 Project Grant to the University of Maryland, College Park on April 10, 2025. The funding supports the development of a rapid, inexpensive microfluidic technology to isolate bacteria directly from whole blood, identify pathogens, and evaluate their antibiotic response within 75 minutes. This will enable clinicians to move...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $750,000 Project Grant to The University of Southern Mississippi to research the role of extracellular polyphosphate in Mycobacterium tuberculosis antibiotic tolerance. The 4-year grant, which begins on Sep 20, 2025 and runs through Aug 31, 2029, aims to investigate the metabolic pathways in M. tuberculosis that regulate extracellular...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $721,194 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Florida State University (FSU) to conduct research on membrane protein complexes involved in the cell division process of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The 5-year project, beginning March 1, 2025, aims to structurally characterize the FtsQ-FtsZ and FtsQ-FtsB-FtsL protein...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $149,620 to Towson University to conduct research on the function of bacterial Toll/Interleukin-1 Receptor (TIR) proteins and their potential role in antimicrobial resistance and immune evasion. The key objectives of this 4-year project are to: 1) Determine the effects of the TcpC bacterial TIR protein's NADase activity on bacterial survival within host cells, 2) Identify novel host molecular pathways targeted by TcpC, and 3) Develop course-based undergraduate research experiences (CUREs) to analyze host responses to TcpC and its NADase activity. This research aims to enhance understanding of bacterial virulence mechanisms and inform the development of new therapeutics to regulate bacterial growth or modulate immune responses for treating infectious diseases and immune disorders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $149.6k | 7/31/25 |